首页>
外国专利>
Treatment for diseases relying on discovery that thioredoxin mediates nitric oxide release in cells
Treatment for diseases relying on discovery that thioredoxin mediates nitric oxide release in cells
展开▼
机译:依靠硫氧还蛋白介导细胞中一氧化氮释放的发现来治疗疾病
展开▼
页面导航
摘要
著录项
相似文献
摘要
Patients having a disease associated with high level of thioredoxin system activity or a requirement for nitric oxide, e.g. large cell lymphoma or restenosis, are treated with a thioredoxin reductase inhibitor, e.g. auranofin or arsenic trioxide, and a nitric oxide donating compound, e.g. isosorbide mononitrite or isosorbide dinitrite or nitroglycerin or S-nittrosothiol. Patients having a disease associated with nitric oxide synthase overexpression or increased activity, e.g. Parkinson's disease or septic shock or pancreatic cancer, are treated with Trx/Trx reductase upregulator, e.g. aptamer that binds to thioredoxin reductase inhibitor, and agent causing depletion of nitric oxide (or adduct thereof), e.g. L-NMMA or L-NAME or minocycline or ascorbate or N-acetylcysteine.
展开▼